NOTCH1 and acute lymphoblastic leukemia: Collectively, these results demonstrate the applicability of the thymus-transplantation-based T-ALL platform to the preclinical testing of targeted therapies, and further strengthen the experimental framework for the rational mAb-based targeting of Notch1 signaling based on Notch1 mutational status.